Details

Autor(en) / Beteiligte

• Giannopapas, Vasileios
• Stavrogianni, Konstantina
• Christouli, Niki
• Kitsos, Dimitrios
• Sideri, Eleni
• Bakalidou, Daphne
• Voumvourakis, Konstantinos
• Papagiannopoulou, Georgia
• Tzartos, John
• Paraskevas, Georgios
• Tsivgoulis, Georgios
• Giannopoulos, Sotirios

Titel

Do cardiovascular disease comorbidities affect the cognitive function of Multiple Sclerosis patients?

Ist Teil von

• Journal of clinical neuroscience, 2023-06, Vol.112, p.20-24

Ort / Verlag

Scotland: Elsevier Ltd

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• •CVD comorbidities are common in MS.•Both CVD and MS affect the cognitive function of PwMS.•A sample of PwMS and either none or exactly one CVD comorbidity underwent 2 neuropsychological assessments in the span of one year.•PwMS with CVD had greater cognitive decline and decreased processing speed compared to PwMS with no CVD comorbidities.•Diabetes and dyslipidemia had the highest impairment.•The use of the SMDT is advised since it’s time efficient,it requires minimal training and correlates with MRI findings. Cognitive impairment is a core symptom of multiple sclerosis, leading to disability in 40–70% of patients. The most common cognitive domains affected by MS are information processing speed, complex attention, executive functions and less frequently, episodic declarative memory. Cardiovascular disease comorbidities have been shown to increase the decline rate in many neurological conditions. Our study aims to examine the possible impact of CVD risk factors in the cognitive decline rate of PwMS. Over the course of a year, 248 PwMS with and without Cardiovascular comorbidity were cognitively evaluated using the written version of SDMT and the MoCA. Compared to control, MS patients with comorbid CVD had greater general cognitive decline and decreased processing speed. Patients with comorbid diabetes and dyslipidemia had the highest impairment, followed by those with hypertension, compared to the control group and those patients with a high BMI. The presence of cardiovascular comorbidities and especially dyslipidemia increases the rate of cognitive decline in MS patients. In such cases, patients should be evaluated every 6 months instead of a year and the use of the SDMT is advised since it’s time efficient,it requires minimal training and correlates with MRI findings.